{
    "info": {
        "nct_id": "NCT03500445",
        "official_title": "Open-label, Single-arm, Phase 2 Study of Initial Treatment With Daratumumab (Darzalex), Carfilzomib (Kyprolis), Lenalidomide (Revlimid) and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma Requiring Systemic Chemotherapy",
        "inclusion_criteria": "* Newly diagnosed, previously untreated myeloma requiring systemic chemotherapy\n\n  • Prior treatment of hypercalcemia or spinal cord compression or active and/or aggressively progressing myeloma with corticosteroids or lenalidomide or bortezomib-based regimens does not disqualify the patient (the treatment dose should not exceed the equivalent of 160 mg of dexamethasone in a 4 week period or not more than 1 cycle of Proteasome Inhibitor / Immunomodulatory-based therapy)\n* Both transplant and non-transplant candidates are eligible.\n* Diagnosis of symptomatic multiple myeloma as per current International Myeloma Working Group (IMWG) uniform criteria prior to initial treatment\n* Monoclonal plasma cells in the Bone Marrow (BM) ≥ 10% or presence of a biopsy-proven plasmacytoma\n* Measurable disease, prior to initial treatment as indicated by one or more of the following:\n\n  * Serum M-protein ≥ 1 g/dL\n  * Urine M-protein ≥ 200 mg/24 hours\n  * If serum protein electrophoresis is felt to be unreliable for routine M-protein measurement, then quantitative immunoglobulin levels are acceptable\n  * Serum freelite measurable disease as per current IMWG criteria\n* Bone marrow specimen will be required at study entry; available DNA sample from pre-induction BM will be used for calibration step for MRD evaluation by gene sequencing.\n* Males and females ≥ 18 years of age\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n* Adequate hepatic function, with bilirubin ≤ 1.5 x upper limit of normal (ULN) and aspirate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x ULN\n* Absolute Neutrophil Count (ANC) ≥ 1.0 x 109/L, hemoglobin ≥ 8 g/dL, platelet count ≥ 75 x 109/L.\n* Calculated creatinine clearance (by Cockroft-Gault) ≥ 50 mL/min or serum creatinine below 2 g/dL\n* Woman of childbearing potential must have 2 negative pregnancy tests prior to initiating lenalidomide.\n* Woman of childbearing potential must agree to use 2 reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual intercourse during the following time periods related to this study: 1) for at least 28 days before starting lenalidomide; 2) while participating in the study; and 3) for at least 30 days after discontinuation from the study.\n* Male subjects must agree to use a latex condom during sexual contact with females of childbearing potential while participating in the study and for at least 90 days following discontinuation from the study even if he has undergone a successful vasectomy.\n* All study participants in the US must be consented to and registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS®) program and be willing and able to comply with the requirements of Revlimid REMS®.\n* Voluntary written informed consent.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Frail non-transplant candidates, defined as in Palumbo et al, Blood 2015.\n* Non-secretory or hyposecretory multiple myeloma, prior to initial treatment defined as <1.0 g/dL M-protein in serum, <200 mg/24 hr urine M-protein, and no measurable disease as per IMWG by Freelite.\n* POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)\n* Amyloidosis\n* Plasma cell leukemia\n* Waldenström's macroglobulinemia or Immunoglobulin M-producing (IgM) myeloma\n* Radiotherapy to multiple sites or immunotherapy within 4 weeks before start of protocol treatment (localized radiotherapy to a single site at least 1 week before start is permissible)\n* Participation in an investigational therapeutic study within 3 weeks or within 5 drug half-lives (t1/2) prior to first dose, whichever time is greater\n* Potential subjects with evidence of progressive disease as per IMWG criteria\n* Patients not able to tolerate daratumumab, carfilzomib, lenalidomide or dexamethasone\n* Peripheral neuropathy ≥ Grade 2 at screening\n* Diarrhea > Grade 1 in the absence of antidiarrheals\n* Central Nervous System (CNS) involvement\n* Pregnant or lactating females\n* Major surgery within 3 weeks prior to first dose.\n* Myocardial infarction within 6 months prior to enrollment, New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities\n* Prior or concurrent pulmonary embolism\n* Known moderate or severe persistent asthma or known chronic obstructive pulmonary disease (COPD)\n\n  * Known or suspected chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) <50% of predicted normal\n  * Moderate or severe persistent asthma within the past 2 years, or currently has uncontrolled asthma of any classification. Note that subjects who currently have controlled intermittent asthma or controlled mild persistent asthma are allowed in the study.\n* Rate-corrected QT interval of electrocardiograph (QTc) > 470 msec on a 12-lead ECG during screening\n* Uncontrolled hypertension or diabetes\n* Acute infection requiring systemic antibiotics, antivirals, or antifungals within two weeks prior to first dose\n* Known seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV). Patients who are seropositive because of hepatitis B virus vaccine are eligible.\n* Non-hematologic malignancy or non-myeloma hematologic malignancy within the past 3 years except a) adequately treated basal cell, squamous cell skin cancer, thyroid cancer, carcinoma in situ of the cervix, or prostate cancer < Gleason Grade 6 with stable prostate specific antigen levels or cancer considered cured by surgical resection alone\n* Any clinically significant medical disease or condition that, in the Investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "• Prior treatment of hypercalcemia or spinal cord compression or active and/or aggressively progressing myeloma with corticosteroids or lenalidomide or bortezomib-based regimens does not disqualify the patient (the treatment dose should not exceed the equivalent of 160 mg of dexamethasone in a 4 week period or not more than 1 cycle of Proteasome Inhibitor / Immunomodulatory-based therapy)",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment of hypercalcemia ... does not disqualify the patient",
                    "criterion": "prior treatment of hypercalcemia",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior treatment of ... spinal cord compression ... does not disqualify the patient",
                    "criterion": "prior treatment of spinal cord compression",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior treatment of ... active and/or aggressively progressing myeloma ... does not disqualify the patient",
                    "criterion": "prior treatment of active and/or aggressively progressing myeloma",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "the treatment dose should not exceed the equivalent of 160 mg of dexamethasone in a 4 week period",
                    "criterion": "corticosteroid treatment dose",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 160,
                                "unit": "mg dexamethasone in 4 week period"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "not more than 1 cycle of Proteasome Inhibitor / Immunomodulatory-based therapy",
                    "criterion": "Proteasome Inhibitor / Immunomodulatory-based therapy cycles",
                    "requirements": [
                        {
                            "requirement_type": "number of cycles",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "cycle"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Calculated creatinine clearance (by Cockroft-Gault) ≥ 50 mL/min or serum creatinine below 2 g/dL",
            "criterions": [
                {
                    "exact_snippets": "Calculated creatinine clearance (by Cockroft-Gault) ≥ 50 mL/min",
                    "criterion": "calculated creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockroft-Gault"
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "mL/min"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "serum creatinine below 2 g/dL",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Woman of childbearing potential must agree to use 2 reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual intercourse during the following time periods related to this study: 1) for at least 28 days before starting lenalidomide; 2) while participating in the study; and 3) for at least 30 days after discontinuation from the study.",
            "criterions": [
                {
                    "exact_snippets": "Woman of childbearing potential must agree to use 2 reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual intercourse",
                    "criterion": "contraception or abstinence agreement",
                    "requirements": [
                        {
                            "requirement_type": "agreement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "contraception_methods",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "reliable forms"
                            }
                        },
                        {
                            "requirement_type": "abstinence_from_heterosexual_intercourse",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "during the following time periods ... 1) for at least 28 days before starting lenalidomide; 2) while participating in the study; and 3) for at least 30 days after discontinuation from the study.",
                    "criterion": "duration of contraception or abstinence",
                    "requirements": [
                        {
                            "requirement_type": "time_periods",
                            "expected_value": [
                                "at least 28 days before starting lenalidomide",
                                "while participating in the study",
                                "at least 30 days after discontinuation from the study"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Voluntary written informed consent.",
            "criterions": [
                {
                    "exact_snippets": "Voluntary written informed consent",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "voluntary",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "written",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum freelite measurable disease as per current IMWG criteria",
            "criterions": [
                {
                    "exact_snippets": "Serum freelite measurable disease as per current IMWG criteria",
                    "criterion": "serum freelite measurable disease",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": "as per current IMWG criteria"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum M-protein ≥ 1 g/dL",
            "criterions": [
                {
                    "exact_snippets": "Serum M-protein ≥ 1 g/dL",
                    "criterion": "serum M-protein",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Bone marrow specimen will be required at study entry; available DNA sample from pre-induction BM will be used for calibration step for MRD evaluation by gene sequencing.",
            "criterions": [
                {
                    "exact_snippets": "Bone marrow specimen will be required at study entry",
                    "criterion": "bone marrow specimen",
                    "requirements": [
                        {
                            "requirement_type": "availability at study entry",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "available DNA sample from pre-induction BM will be used for calibration step for MRD evaluation by gene sequencing",
                    "criterion": "DNA sample from pre-induction bone marrow",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Both transplant and non-transplant candidates are eligible.",
            "criterions": [
                {
                    "exact_snippets": "Both transplant and non-transplant candidates are eligible.",
                    "criterion": "transplant candidacy",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "transplant candidate",
                                "non-transplant candidate"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Urine M-protein ≥ 200 mg/24 hours",
            "criterions": [
                {
                    "exact_snippets": "Urine M-protein ≥ 200 mg/24 hours",
                    "criterion": "urine M-protein",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 200,
                                "unit": "mg/24 hours"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Male subjects must agree to use a latex condom during sexual contact with females of childbearing potential while participating in the study and for at least 90 days following discontinuation from the study even if he has undergone a successful vasectomy.",
            "criterions": [
                {
                    "exact_snippets": "Male subjects",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    ]
                },
                {
                    "exact_snippets": "must agree to use a latex condom during sexual contact with females of childbearing potential while participating in the study and for at least 90 days following discontinuation from the study even if he has undergone a successful vasectomy",
                    "criterion": "latex condom use during sexual contact with females of childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "agreement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "during study"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 90,
                                        "unit": "days after discontinuation"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Newly diagnosed, previously untreated myeloma requiring systemic chemotherapy",
            "criterions": [
                {
                    "exact_snippets": "Newly diagnosed",
                    "criterion": "myeloma diagnosis status",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis status",
                            "expected_value": "newly diagnosed"
                        }
                    ]
                },
                {
                    "exact_snippets": "previously untreated",
                    "criterion": "myeloma treatment history",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "myeloma requiring systemic chemotherapy",
                    "criterion": "myeloma requiring systemic chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "requirement for systemic chemotherapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0-1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Measurable disease, prior to initial treatment as indicated by one or more of the following:",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease, prior to initial treatment",
                    "criterion": "disease",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "status",
                            "expected_value": "prior to initial treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* All study participants in the US must be consented to and registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS®) program and be willing and able to comply with the requirements of Revlimid REMS®.",
            "criterions": [
                {
                    "exact_snippets": "All study participants in the US must be consented to and registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS®) program",
                    "criterion": "Revlimid REMS program participation",
                    "requirements": [
                        {
                            "requirement_type": "consent",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "registration",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "be willing and able to comply with the requirements of Revlimid REMS®",
                    "criterion": "Revlimid REMS program compliance",
                    "requirements": [
                        {
                            "requirement_type": "willingness to comply",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability to comply",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Monoclonal plasma cells in the Bone Marrow (BM) ≥ 10% or presence of a biopsy-proven plasmacytoma",
            "criterions": [
                {
                    "exact_snippets": "Monoclonal plasma cells in the Bone Marrow (BM) ≥ 10%",
                    "criterion": "monoclonal plasma cells in the bone marrow",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "%"
                            }
                        },
                        {
                            "requirement_type": "location",
                            "expected_value": "bone marrow"
                        }
                    ]
                },
                {
                    "exact_snippets": "presence of a biopsy-proven plasmacytoma",
                    "criterion": "biopsy-proven plasmacytoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* If serum protein electrophoresis is felt to be unreliable for routine M-protein measurement, then quantitative immunoglobulin levels are acceptable",
            "criterions": [
                {
                    "exact_snippets": "serum protein electrophoresis is felt to be unreliable for routine M-protein measurement",
                    "criterion": "serum protein electrophoresis",
                    "requirements": [
                        {
                            "requirement_type": "reliability for routine M-protein measurement",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "quantitative immunoglobulin levels are acceptable",
                    "criterion": "quantitative immunoglobulin levels",
                    "requirements": [
                        {
                            "requirement_type": "acceptability as alternative measurement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Woman of childbearing potential must have 2 negative pregnancy tests prior to initiating lenalidomide.",
            "criterions": [
                {
                    "exact_snippets": "Woman of childbearing potential",
                    "criterion": "sex and reproductive potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must have 2 negative pregnancy tests prior to initiating lenalidomide",
                    "criterion": "pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "number of tests",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "tests"
                            }
                        },
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to initiating lenalidomide"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Diagnosis of symptomatic multiple myeloma as per current International Myeloma Working Group (IMWG) uniform criteria prior to initial treatment",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of symptomatic multiple myeloma",
                    "criterion": "multiple myeloma",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "as per current International Myeloma Working Group (IMWG) uniform criteria",
                    "criterion": "IMWG uniform criteria for multiple myeloma",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis according to IMWG criteria",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "prior to initial treatment",
                    "criterion": "treatment status",
                    "requirements": [
                        {
                            "requirement_type": "treatment-naive",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Males and females ≥ 18 years of age",
            "criterions": [
                {
                    "exact_snippets": "Males and females",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "allowed_values",
                            "expected_value": [
                                "male",
                                "female"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "≥ 18 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate hepatic function, with bilirubin ≤ 1.5 x upper limit of normal (ULN) and aspirate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x ULN",
            "criterions": [
                {
                    "exact_snippets": "Adequate hepatic function",
                    "criterion": "hepatic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "bilirubin ≤ 1.5 x upper limit of normal (ULN)",
                    "criterion": "bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "aspirate aminotransferase (AST) ... ≤ 3 x ULN",
                    "criterion": "aspartate aminotransferase (AST)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine aminotransferase (ALT) ≤ 3 x ULN",
                    "criterion": "alanine aminotransferase (ALT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Prior or concurrent pulmonary embolism",
            "criterions": [
                {
                    "exact_snippets": "Prior or concurrent pulmonary embolism",
                    "criterion": "pulmonary embolism",
                    "requirements": [
                        {
                            "requirement_type": "history or presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Central Nervous System (CNS) involvement",
            "criterions": [
                {
                    "exact_snippets": "Central Nervous System (CNS) involvement",
                    "criterion": "Central Nervous System (CNS) involvement",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known moderate or severe persistent asthma or known chronic obstructive pulmonary disease (COPD)",
            "criterions": [
                {
                    "exact_snippets": "Known moderate or severe persistent asthma",
                    "criterion": "asthma",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "moderate",
                                "severe"
                            ]
                        },
                        {
                            "requirement_type": "persistence",
                            "expected_value": "persistent"
                        },
                        {
                            "requirement_type": "known_diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known chronic obstructive pulmonary disease (COPD)",
                    "criterion": "chronic obstructive pulmonary disease (COPD)",
                    "requirements": [
                        {
                            "requirement_type": "known_diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled hypertension or diabetes",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled hypertension",
                    "criterion": "hypertension",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "Uncontrolled ... diabetes",
                    "criterion": "diabetes",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any clinically significant medical disease or condition that, in the Investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent.",
            "criterions": [
                {
                    "exact_snippets": "Any clinically significant medical disease or condition",
                    "criterion": "clinically significant medical disease or condition",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "in the Investigator's opinion, may interfere with protocol adherence",
                    "criterion": "potential to interfere with protocol adherence",
                    "requirements": [
                        {
                            "requirement_type": "investigator judgment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "in the Investigator's opinion, may interfere with ... a subject's ability to give informed consent",
                    "criterion": "potential to interfere with ability to give informed consent",
                    "requirements": [
                        {
                            "requirement_type": "investigator judgment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Plasma cell leukemia",
            "criterions": [
                {
                    "exact_snippets": "Plasma cell leukemia",
                    "criterion": "plasma cell leukemia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Acute infection requiring systemic antibiotics, antivirals, or antifungals within two weeks prior to first dose",
            "criterions": [
                {
                    "exact_snippets": "Acute infection requiring systemic antibiotics, antivirals, or antifungals within two weeks prior to first dose",
                    "criterion": "acute infection",
                    "requirements": [
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": [
                                "systemic antibiotics",
                                "antivirals",
                                "antifungals"
                            ]
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "weeks"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Frail non-transplant candidates, defined as in Palumbo et al, Blood 2015.",
            "criterions": [
                {
                    "exact_snippets": "Frail non-transplant candidates, defined as in Palumbo et al, Blood 2015.",
                    "criterion": "frailty status (per Palumbo et al, Blood 2015)",
                    "requirements": [
                        {
                            "requirement_type": "frailty classification",
                            "expected_value": "frail (as defined by Palumbo et al, Blood 2015)"
                        }
                    ]
                },
                {
                    "exact_snippets": "non-transplant candidates",
                    "criterion": "transplant candidacy",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Moderate or severe persistent asthma within the past 2 years, or currently has uncontrolled asthma of any classification. Note that subjects who currently have controlled intermittent asthma or controlled mild persistent asthma are allowed in the study.",
            "criterions": [
                {
                    "exact_snippets": "Moderate or severe persistent asthma within the past 2 years",
                    "criterion": "persistent asthma",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "moderate",
                                "severe"
                            ]
                        },
                        {
                            "requirement_type": "persistence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "currently has uncontrolled asthma of any classification",
                    "criterion": "asthma control",
                    "requirements": [
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": "current"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV). Patients who are seropositive because of hepatitis B virus vaccine are eligible.",
            "criterions": [
                {
                    "exact_snippets": "Known seropositive for or active viral infection with human immunodeficiency virus (HIV)",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "seropositivity or active infection",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known seropositive for or active viral infection with ... hepatitis B virus (HBV)",
                    "criterion": "hepatitis B virus infection",
                    "requirements": [
                        {
                            "requirement_type": "seropositivity or active infection",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known seropositive for or active viral infection with ... hepatitis C virus (HCV)",
                    "criterion": "hepatitis C virus infection",
                    "requirements": [
                        {
                            "requirement_type": "seropositivity or active infection",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients who are seropositive because of hepatitis B virus vaccine are eligible.",
                    "criterion": "hepatitis B virus seropositivity due to vaccination",
                    "requirements": [
                        {
                            "requirement_type": "cause of seropositivity",
                            "expected_value": "hepatitis B virus vaccine"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Diarrhea > Grade 1 in the absence of antidiarrheals",
            "criterions": [
                {
                    "exact_snippets": "Diarrhea > Grade 1",
                    "criterion": "diarrhea",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "in the absence of antidiarrheals",
                    "criterion": "antidiarrheal use",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known or suspected chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) <50% of predicted normal",
            "criterions": [
                {
                    "exact_snippets": "Known or suspected chronic obstructive pulmonary disease (COPD)",
                    "criterion": "chronic obstructive pulmonary disease (COPD)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis or suspicion",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "forced expiratory volume in 1 second (FEV1) <50% of predicted normal",
                    "criterion": "forced expiratory volume in 1 second (FEV1)",
                    "requirements": [
                        {
                            "requirement_type": "percentage of predicted normal",
                            "expected_value": {
                                "operator": "<",
                                "value": 50,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnant or lactating females",
            "criterions": [
                {
                    "exact_snippets": "Pregnant ... females",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "lactating females",
                    "criterion": "lactation status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Amyloidosis",
            "criterions": [
                {
                    "exact_snippets": "Amyloidosis",
                    "criterion": "amyloidosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Potential subjects with evidence of progressive disease as per IMWG criteria",
            "criterions": [
                {
                    "exact_snippets": "evidence of progressive disease as per IMWG criteria",
                    "criterion": "progressive disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "diagnostic_criteria",
                            "expected_value": "IMWG criteria"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major surgery within 3 weeks prior to first dose.",
            "criterions": [
                {
                    "exact_snippets": "Major surgery within 3 weeks prior to first dose.",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients not able to tolerate daratumumab, carfilzomib, lenalidomide or dexamethasone",
            "criterions": [
                {
                    "exact_snippets": "not able to tolerate daratumumab",
                    "criterion": "daratumumab tolerance",
                    "requirements": [
                        {
                            "requirement_type": "tolerance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "not able to tolerate ... carfilzomib",
                    "criterion": "carfilzomib tolerance",
                    "requirements": [
                        {
                            "requirement_type": "tolerance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "not able to tolerate ... lenalidomide",
                    "criterion": "lenalidomide tolerance",
                    "requirements": [
                        {
                            "requirement_type": "tolerance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "not able to tolerate ... dexamethasone",
                    "criterion": "dexamethasone tolerance",
                    "requirements": [
                        {
                            "requirement_type": "tolerance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Non-secretory or hyposecretory multiple myeloma, prior to initial treatment defined as <1.0 g/dL M-protein in serum, <200 mg/24 hr urine M-protein, and no measurable disease as per IMWG by Freelite.",
            "criterions": [
                {
                    "exact_snippets": "Non-secretory or hyposecretory multiple myeloma",
                    "criterion": "multiple myeloma type",
                    "requirements": [
                        {
                            "requirement_type": "subtype",
                            "expected_value": [
                                "non-secretory",
                                "hyposecretory"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "prior to initial treatment",
                    "criterion": "treatment status",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "<1.0 g/dL M-protein in serum",
                    "criterion": "serum M-protein level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.0,
                                "unit": "g/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "<200 mg/24 hr urine M-protein",
                    "criterion": "urine M-protein level (24 hr)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 200,
                                "unit": "mg/24 hr"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "no measurable disease as per IMWG by Freelite",
                    "criterion": "measurable disease (IMWG by Freelite)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participation in an investigational therapeutic study within 3 weeks or within 5 drug half-lives (t1/2) prior to first dose, whichever time is greater",
            "criterions": [
                {
                    "exact_snippets": "Participation in an investigational therapeutic study within 3 weeks or within 5 drug half-lives (t1/2) prior to first dose, whichever time is greater",
                    "criterion": "participation in an investigational therapeutic study",
                    "requirements": [
                        {
                            "requirement_type": "time since last participation",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "drug half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Radiotherapy to multiple sites or immunotherapy within 4 weeks before start of protocol treatment (localized radiotherapy to a single site at least 1 week before start is permissible)",
            "criterions": [
                {
                    "exact_snippets": "Radiotherapy to multiple sites ... within 4 weeks before start of protocol treatment",
                    "criterion": "radiotherapy to multiple sites",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "immunotherapy within 4 weeks before start of protocol treatment",
                    "criterion": "immunotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "localized radiotherapy to a single site at least 1 week before start is permissible",
                    "criterion": "localized radiotherapy to a single site",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "week"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Myocardial infarction within 6 months prior to enrollment, New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities",
            "criterions": [
                {
                    "exact_snippets": "Myocardial infarction within 6 months prior to enrollment",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "New York Heart Association (NYHA) Class III or IV heart failure",
                    "criterion": "heart failure (NYHA class)",
                    "requirements": [
                        {
                            "requirement_type": "NYHA class",
                            "expected_value": [
                                "III",
                                "IV"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled angina",
                    "criterion": "angina",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "severe uncontrolled ventricular arrhythmias",
                    "criterion": "ventricular arrhythmias",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        },
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "electrocardiographic evidence of acute ischemia",
                    "criterion": "acute ischemia (on ECG)",
                    "requirements": [
                        {
                            "requirement_type": "evidence on ECG",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "electrocardiographic evidence of ... active conduction system abnormalities",
                    "criterion": "conduction system abnormalities (on ECG)",
                    "requirements": [
                        {
                            "requirement_type": "evidence on ECG",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Rate-corrected QT interval of electrocardiograph (QTc) > 470 msec on a 12-lead ECG during screening",
            "criterions": [
                {
                    "exact_snippets": "Rate-corrected QT interval of electrocardiograph (QTc) > 470 msec on a 12-lead ECG during screening",
                    "criterion": "rate-corrected QT interval (QTc)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 470,
                                "unit": "msec"
                            }
                        },
                        {
                            "requirement_type": "measurement context",
                            "expected_value": "on a 12-lead ECG during screening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)",
            "criterions": [
                {
                    "exact_snippets": "POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)",
                    "criterion": "POEMS syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "polyneuropathy",
                    "criterion": "polyneuropathy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "organomegaly",
                    "criterion": "organomegaly",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "endocrinopathy",
                    "criterion": "endocrinopathy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "monoclonal protein",
                    "criterion": "monoclonal protein",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "skin changes",
                    "criterion": "skin changes",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Non-hematologic malignancy or non-myeloma hematologic malignancy within the past 3 years except a) adequately treated basal cell, squamous cell skin cancer, thyroid cancer, carcinoma in situ of the cervix, or prostate cancer < Gleason Grade 6 with stable prostate specific antigen levels or cancer considered cured by surgical resection alone",
            "criterions": [
                {
                    "exact_snippets": "Non-hematologic malignancy or non-myeloma hematologic malignancy within the past 3 years",
                    "criterion": "history of non-hematologic malignancy or non-myeloma hematologic malignancy",
                    "requirements": [
                        {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "except a) adequately treated basal cell, squamous cell skin cancer, thyroid cancer, carcinoma in situ of the cervix, or prostate cancer < Gleason Grade 6 with stable prostate specific antigen levels or cancer considered cured by surgical resection alone",
                    "criterion": "history of specific cancers (basal cell, squamous cell skin cancer, thyroid cancer, carcinoma in situ of the cervix, prostate cancer < Gleason Grade 6 with stable PSA, or cancer cured by surgery)",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "adequately treated or considered cured by surgical resection alone"
                        },
                        {
                            "requirement_type": "cancer type",
                            "expected_value": [
                                "basal cell skin cancer",
                                "squamous cell skin cancer",
                                "thyroid cancer",
                                "carcinoma in situ of the cervix",
                                "prostate cancer < Gleason Grade 6 with stable PSA"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Peripheral neuropathy ≥ Grade 2 at screening",
            "criterions": [
                {
                    "exact_snippets": "Peripheral neuropathy ≥ Grade 2 at screening",
                    "criterion": "peripheral neuropathy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "CTCAE grade"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at screening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Waldenström's macroglobulinemia or Immunoglobulin M-producing (IgM) myeloma",
            "criterions": [
                {
                    "exact_snippets": "Waldenström's macroglobulinemia",
                    "criterion": "Waldenström's macroglobulinemia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Immunoglobulin M-producing (IgM) myeloma",
                    "criterion": "Immunoglobulin M-producing (IgM) myeloma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "* Absolute Neutrophil Count (ANC) ≥ 1.0 x 109/L, hemoglobin ≥ 8 g/dL, platelet count ≥ 75 x 109/L.",
            "criterions": [
                {
                    "exact_snippets": "Absolute Neutrophil Count (ANC) ≥ 1.0 x 10^9/L",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.0,
                                "unit": "x 10^9/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "hemoglobin ≥ 8 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 8,
                                "unit": "g/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "platelet count ≥ 75 x 10^9/L",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 75,
                                "unit": "x 10^9/L"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}